What is SHOT?
SHOT is a modified form of hyperbaric oxygen therapy. Most conventional hyperbaric technologies involve surrounding a patient inside some form of enclosure and filling that enclosure with a compressed gas like oxygen, or room air. SHOT differs fundamentally from that method by placing a patient inside a sealed chamber. Filling the chamber with pressurized water, while the patient breathes pressurized oxygen through a mask. This artificially creates an environment similar to scuba diving.
SHOT advantages?
The SHOT concept has the following advantages:
1) no fire/explosion risk since the patient is completely surrounded with pressurized water
2) capable of delivering medical grade hyperbaric oxygen therapy (up to 3.0 atmospheres)
3) minimal oxygen consumption (typically less than 10 liters per minute)
Those 3 advantages will lead to the 4th advantage which is the ability to deploy SHOT chambers on a much larger scale.
Is SHOT patented?
SHOT is patented in the United States (USPTO # 11,872,164 B2) and Canada (CIPO # 3114035). Patent approval in Canada was obtained in March of 2022, and in the United States in January of 2024.
SHOT stage of development?
SHOT is currently in the concept design phase preceding the development of a prototype.
SHOT history
The SHOT concept was created by inventor Marc Garrity in 2021. The SHOT concept is owned by 2388634 Alberta Limited, which is solely owned by Marc Garrity.
What is HBOT?
Hyperbaric Oxygen Therapy is an approved treatment used worldwide, for a variety of medical conditions. However, there are a number of "off-label" indications for HBOT that do not have proper research trials supporting HBOT's use. If those research trials were completed, there will likely be a surge in demand for HBOT that will exceed current infrastructure's capacity. Some of these off-label indications are as an adjunct to cancer therapy, traumatic brain injuries, Alzheimer's, Long COVID, post-myocardial infarction, fertility issues, aging, and toxic gas exposure. SHOT has the potential to fulfill society's need for a widely available source of HBOT that is easy to deploy.